Glycopeptide-resistant Enterococcus in Europe: An increasing nosocomial problem;Enterococcus resistentes a glucopéptidos en Europa: Un problema hospitalario creciente

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 8, 2005, Pages 457-459

  Francia, María Victoria ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; VANCOMYCIN;

EDITORIAL; ENTEROCOCCUS; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS GALLINARUM; EUROPE; HOSPITAL INFECTION; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 27544444898     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078821     Document Type: Editorial

References (44)

1. Shepard BD, Gilmore MS. Antibiotic-resistant enterococci: the mechanisms and dynamics of drug introduction and resistance. Microbes Infect. 2002;4:215-24.
2. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988; 319:157-61.
3. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13:686-707.
4. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32 Suppl 2:133-45.
5. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis. 2001;7:183-7.
6. Goossens H. The epidemiology of vancomycin-resistant enterococci. Curr Opin Infect Dis. 1999;12:537-41.
7. Chavers LS, Moser SA, Benjamin WH, Banks SE, Steinhauer JR, Smith AM, et al. Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect. 2003;53:159-71.
8. Klare I, Konstabel C, Badstubner D, Werner G, Witte W. Occurrence and spread of antibiotic resistances in Enterococcus faecium. Int J Food Microbiol. 2003;88:269-90.
9. Bartley J. First case of VRSA identified in Michigan. Infect Control Hosp Epidemiol. 2002;23:480.
10. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-7.
11. Flannagan SE, Chow JW, Donabedian SM, Brown WJ, Perri MB, Zervos MJ, et al. Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype. Antimicrob Agents Chemother. 2003;47:3954-9.
12. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother. 2004;48:275-80.
13. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science. 2003;302:1569-71.
14. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist. 2001;7:229-36.
15. Wegener HC, Aarestrup FM, Jensen LB, Hammerum AM, Eager F. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis. 1999;5:329-35.
16. Carias LL, Rudin SD, Donskey CJ, Rice LB. Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol. 1998;180:4426-34.
17. Hanrahan J, Hoyen C, Rice LB. Geographic distribution of a large mobile element that transfers ampicillin and vancomycin resistance between Enterococcus faecium strains. Antimicrob Agents Chemother. 2000;44:1349-51.
18. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis. 2000;31:1058-65.
19. Biavasco F, Miele A, Vignaroli C, Manso E, Lupidi R, Varaldo PE. Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis. Microb Drug Resist. 1996;2:231-7.
20. Mundy LM, Sahm DF, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev. 2000;13:513-22.
21. Méndez-Álvarez S, Pérez-Hernández X, Claverie-Martin F. Glycopeptide resistance in enterococci. Int Microbiol. 2000;3:71-80.
22. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother. 2003;51 Suppl 3:13-21.
23. Cisterna R, Ibarra K, Morla A, Basaras M, Cisterna C, Herreras A, et al. [Multicenter study of resistance in enterococci. The role of teicoplanin. Spanish Group for Study and Surveillance of Resistance]. Rev Esp Quimioter. 1999;12:237-43.
24. Mutnick AH, Biedenbach DJ, Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis. 2003;46:63-8.
25. Gruneberg RN, Hryniewicz W. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Int J Antimicrob Agents. 1998;10:271-7.
26. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis. 2000;19:816-22.
27. Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents. 2004;24:119-24.
28. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - A European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 2004;3:14.
29. Goossens H, Jabes D, Rossi R, Lammens C, Privitera G, Courvalin P. European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates. J Antimicrob Chemother. 2003;51 Suppl 3:5-12.
30. Felmingham D, Brown DF, Soussy CJ. European glycopeptide susceptibility survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group. Diagn Microbiol Infect Dis. 1998;31:563-71.
31. DeLisle S, Perl TM. Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance. Chest. 2003;123:504S-18S.
32. Willems RJL, Top J, Van Santen M, Robinson DA, Coque TM, Baquero F, et al. Global Spread of Vancomycin-resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex. Emerg Infect Dis. En prensa 2005.
33. Ridwan B, Mascini E, Van Der Reijden N, Verhoef J, Bonten M. What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals? BMJ. 2002;324:666-8.
34. Lorenzo-Díaz F, Delgado T, Reyes-Darias JA, Flores C, Méndez-Álvarez S, Villar J, et al. Characterization of the first VanB vancomycin-resistant Enterococcus faecium isolated in a Spanish hospital. Curr Microbiol. 2004;48:199-203.
35. Maseda E, Una R, Ureta P, Royo C. [Enterococcus faecium cholangitis resistant to vancomycin and quinupristin-dalfopristin]. Med Clin (Barc). 2002;119:276-7.
36. Balas D, Perea B, Wilhelmi I, Romanyk J, Alós JI, Gómez-Garcés JL. [Prevalence of antimicrobial resistance in enterococci isolated from blood in Madrid (1994-1995)]. Enferm Infecc Microbiol Clin. 1997;15:22-3.
37. Del Campo R, Tenorio C, Zarazaga M, Gómez-Lus R, Baquero F, Torres C. Detection of a single vanA-containing Enterococcus faecalis clone in hospitals in different regions in Spain. J Antimicrob Chemother. 2001;48:746-7.
38. Pérez-Hernández X, Méndez-Álvarez S, Delgado T, Moreno A, Reyes-Darias A, Sierra López A, et al. Low prevalence of vancomycin-resistant enterococci in clinical samples from hospitalized patients of the Canary Islands, Spain. Int Microbiol. 2002;5:117-20.
39. Aznar E, Buendía B, García-Penuela E, Escudero E, Alarcón T, López-Brea M. Community-acquired urinary tract infection caused by vancomycin-resistant Enterococcus faecalis clinical isolate. Rev Esp Quimioter. 2004;17:263-5.
40. Peset V, Tallon P, Solá C, Sánchez E, Sarrión A, Pérez-Belles C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis. 2000;19:742-9.
41. Velasco D, Pérez S, Ángeles Domínguez M, Villanueva R, Bou G. Description of a nosocomial outbreak of infection caused by a vanA-containing strain of Enterococcus faecalis in La Coruña, Spain. J Antimicrob Chemother. 2004; 53:892-3.
42. Francia MV, Calvo J, García C, Ugalde E, Monteagudo I, Campo AB, et al. 2005. Glycopeptide-resistant Enterococcus faecium in Spain with vanA genotype and apparent teicoplanin susceptibility. En: 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen.
43. Baquero F. Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health. Clin Infect Dis. 1996;23:819-23.
44. Maciá MD, Juan C, Oliver A, Hidalgo O, Pérez JL. Caracterización molecular de un brote por Enterococcus faecalis resistente a los glucopéptidos en una unidad de cuidados intensives. Enferm Infecc Microbiol Clin. 2005;23:460-3.